These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 15920495)
1. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495 [TBL] [Abstract][Full Text] [Related]
2. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245 [TBL] [Abstract][Full Text] [Related]
3. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639 [TBL] [Abstract][Full Text] [Related]
4. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843 [TBL] [Abstract][Full Text] [Related]
6. Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent. Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Suzumura T; Horii T; Shirai N; Maekawa M; Yada Y; Teshima H; Takeuchi J; Ohnishi K; Ohno R Int J Hematol; 2005 Dec; 82(5):445-8. PubMed ID: 16533750 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049 [TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Breccia M; Lo-Coco F Expert Opin Biol Ther; 2011 Feb; 11(2):225-34. PubMed ID: 21142804 [TBL] [Abstract][Full Text] [Related]
9. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Lo Coco F; Ammatuna E; Noguera N Clin Adv Hematol Oncol; 2006 Jan; 4(1):57-62, 76-7. PubMed ID: 16562371 [TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A. Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758 [TBL] [Abstract][Full Text] [Related]
11. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431 [TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia. Habib A; Hamade E; Mahfouz R; Nasrallah MS; de Thé H; Bazarbachi A Leukemia; 2008 Jun; 22(6):1125-30. PubMed ID: 18354491 [TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552 [TBL] [Abstract][Full Text] [Related]
14. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132 [TBL] [Abstract][Full Text] [Related]